Identification of baseline gene expression signatures predicting therapeutic responses to three biologic agents in rheumatoid arthritis: a retrospective observational study

According to EULAR recommendations, biologic DMARDs (bDMARDs) such as tumor necrosis factor inhibitor, tocilizumab (TCZ), and abatacept (ABT) are in parallel when prescribing to rheumatoid arthritis (RA) patients who have shown insufficient response to conventional synthetic DMARDs. However, most pr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Arthritis research & therapy 2016-07, Vol.18 (1), p.159-159, Article 159
Hauptverfasser:	Nakamura, Seiji, Suzuki, Katsuya, Iijima, Hiroshi, Hata, Yuko, Lim, Chun Ren, Ishizawa, Yohei, Kameda, Hideto, Amano, Koichi, Matsubara, Kenichi, Matoba, Ryo, Takeuchi, Tsutomu
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept - therapeutic use Adult Aged Antibodies, Monoclonal, Humanized - therapeutic use Antirheumatic Agents - therapeutic use Area Under Curve Arthritis Arthritis, Rheumatoid - drug therapy Arthritis, Rheumatoid - genetics Biomarkers - analysis Complications and side effects Dosage and administration Drug therapy Female Gene expression Gene Expression Profiling Genetic aspects Humans Infliximab Infliximab - therapeutic use Male Middle Aged Oligonucleotide Array Sequence Analysis Physiological aspects Polymerase Chain Reaction Retrospective Studies Rheumatoid arthritis ROC Curve Sensitivity and Specificity Transcriptome Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!